Actuate Therapeutics ACTU

NASDAQ ACTU

$1.26 -0.11 (-8.03%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap35.54 Mn

P/E-1.70

Div. Yield0.00

Add ratio to table…

About

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase 3 (GSK3). The company's lead asset is elraglusib, an ATP-competitive small molecule designed to enter cancer cells and block the function of the GSK3 beta enzyme, a regulator of signaling pathways that promote tumor cell survival, growth, migration, and…

Actuate Therapeutics, Inc. currently does not generate revenue from product sales as it remains in the clinical development stage. The company's financial resources are derived from equity financing, potential milestone payments under license agreements, and collaborations with research institutions and pharmaceutical partners.

Actuate Therapeutics, Inc. operates in the competitive oncology biopharmaceutical sector where it faces established chemotherapy regimens such as gemcitabine nab paclitaxel (GnP), FOLFIRINOX, and NALIRIFOX, as well as emerging targeted therapies including daraxonrasib, quemliclustat, and atebimetinib that are being evaluated in clinical trials for pancreatic cancer and other solid tumors. The company believes its competitive advantages stem from elraglusib's novel mechanism as a GSK3 inhibitor with multimodal activity, the breadth of potential indications demonstrated in preclinical and clinical data, and regulatory incentives such as orphan drug designations for pancreatic and pediatric cancers and fast track designation for metastatic pancreatic adenocarcinoma, which together aim to differentiate its product candidates from existing therapies.

Actuate Therapeutics, Inc. serves patients with advanced cancers, healthcare providers, hospitals, and oncology clinics that administer its investigational therapies through clinical trials and, pending approval, would prescribe its products for treatment. The company collaborates with institutions such as UPMC Hillman Cancer Center, Massachusetts General Hospital, the University of Colorado, and the Fred Hutchinson Cancer Center to conduct investigator initiated trials that evaluate elraglusib in combination with standard chemotherapy regimens.

Investment Thesis

▲ Bull case

Actuate Therapeutics possesses a potentially transformative oncology asset in elraglusib, which demonstrated a statistically significant survival benefit in a difficult-to-treat patient population—advanced pancreatic cancer—where therapeutic options remain severely limited. The mid-stage trial showed 44% of patients receiving elraglusib with chemotherapy were alive at one year compared to just 22% on chemotherapy alone, effectively doubling the one-year survival rate. This 22 percentage point absolute improvement represents a clinically meaningful outcome in a disease with historically poor prognosis, suggesting the drug addresses a critical unmet need. The mechanism of action—GSK-3 beta inhibition targeting cancer cell survival, tumor growth, and immune evasion—is novel and mechanistically distinct from existing therapies, reducing the likelihood of cross-resistance and supporting potential use in combination regimens. Furthermore, the observation of a median overall survival of 10.1 months versus 7.2 months for chemotherapy alone, coupled with a 38% reduction in the risk of death, provides a strong foundation for Phase 3 development. Most compellingly, the two-year survival data revealed 13% of patients in the elraglusib group remained alive while zero patients in the chemotherapy-only arm survived to that milestone, indicating a potential long-term tail of benefit that could reshape expectations for durable responses in pancreatic cancer. This depth of response hints at biological activity beyond mere cytostatic effects, possibly involving immune modulation or tumor microenvironment remodeling, which could support broader development strategies.
Beyond pancreatic cancer, elraglusib’s mechanism of inhibiting GSK-3 beta—a node implicated in multiple oncogenic pathways including Wnt, NF-κB, and HIF-1α signaling—suggests applicability across a range of solid tumors, a point explicitly raised by the study’s lead investigator. GSK-3 beta dysregulation is prevalent in colorectal, breast, lung, and prostate cancers, among others, creating a rationale for basket or tumor-agnostic trials that could accelerate development and expand the addressable patient population. The drug’s ability to counteract immune evasion may also position it favorably for combination with immunotherapy agents, such as checkpoint inhibitors, particularly in immunologically "cold" tumors like pancreatic cancer where monotherapy has largely failed. Early-phase data showing activity in monotherapy settings (implied by the trial design adding elraglusib to chemo) suggest it retains efficacy as a single agent, which would be valuable in later-line settings or for patients ineligible for aggressive chemotherapy. Given the high unmet need and poor prognosis in pancreatic cancer, regulatory pathways such as accelerated approval based on overall survival or progression-free survival endpoints in Phase 3 could be attainable, especially if the survival benefit is replicated or improved upon. The absence of a recent earnings call means the market has not had an opportunity to fully digest these results, creating a potential information gap where the true value of the pipeline is not yet reflected in the stock price—particularly if upcoming milestones like Phase 3 trial initiation or interim data readouts are anticipated but not yet priced in.

Actuate Therapeutics possesses a potentially transformative oncology asset in elraglusib, which demonstrated a statistically significant survival benefit in a difficult-to-treat patient population—advanced pancreatic cancer—where therapeutic options remain severely limited. The mid-stage trial showed 44% of patients receiving elraglusib with chemotherapy were alive at one year compared to just 22% on chemotherapy alone, effectively doubling the one-year survival rate. This 22 percentage point absolute improvement represents a clinically meaningful outcome in a disease with historically poor prognosis, suggesting the drug addresses a critical unmet need. The mechanism of action—GSK-3 beta inhibition targeting cancer cell survival, tumor growth, and immune evasion—is novel and mechanistically distinct from existing therapies, reducing the likelihood of cross-resistance and supporting potential use in combination regimens. Furthermore, the observation of a median overall survival of 10.1 months versus 7.2 months for chemotherapy alone, coupled with a 38% reduction in the risk of death, provides a strong foundation for Phase 3 development. Most compellingly, the two-year survival data revealed 13% of patients in the elraglusib group remained alive while zero patients in the chemotherapy-only arm survived to that milestone, indicating a potential long-term tail of benefit that could reshape expectations for durable responses in pancreatic cancer. This depth of response hints at biological activity beyond mere cytostatic effects, possibly involving immune modulation or tumor microenvironment remodeling, which could support broader development strategies.
Beyond pancreatic cancer, elraglusib’s mechanism of inhibiting GSK-3 beta—a node implicated in multiple oncogenic pathways including Wnt, NF-κB, and HIF-1α signaling—suggests applicability across a range of solid tumors, a point explicitly raised by the study’s lead investigator. GSK-3 beta dysregulation is prevalent in colorectal, breast, lung, and prostate cancers, among others, creating a rationale for basket or tumor-agnostic trials that could accelerate development and expand the addressable patient population. The drug’s ability to counteract immune evasion may also position it favorably for combination with immunotherapy agents, such as checkpoint inhibitors, particularly in immunologically "cold" tumors like pancreatic cancer where monotherapy has largely failed. Early-phase data showing activity in monotherapy settings (implied by the trial design adding elraglusib to chemo) suggest it retains efficacy as a single agent, which would be valuable in later-line settings or for patients ineligible for aggressive chemotherapy. Given the high unmet need and poor prognosis in pancreatic cancer, regulatory pathways such as accelerated approval based on overall survival or progression-free survival endpoints in Phase 3 could be attainable, especially if the survival benefit is replicated or improved upon. The absence of a recent earnings call means the market has not had an opportunity to fully digest these results, creating a potential information gap where the true value of the pipeline is not yet reflected in the stock price—particularly if upcoming milestones like Phase 3 trial initiation or interim data readouts are anticipated but not yet priced in.

▼ Bear case

Despite the promising survival signals in the mid-stage pancreatic cancer trial, Actuate Therapeutics faces substantial hurdles in translating early-phase efficacy into a commercially viable product, particularly given the high failure rate of oncology drugs in Phase 3 development. The trial, while showing a doubling of one-year survival, was still intermediate in size (233 patients) and not designed to support regulatory approval; thus, any positive outcome would require replication in a larger, pivotal trial that could take years to complete and enroll, especially in a competitive landscape where multiple companies are pursuing novel pancreatic cancer therapies. The fact that only 13% of patients were alive at two years in the drug group—while dramatically better than zero in the control arm—still underscores the modest absolute benefit in long-term survival, raising questions about whether the drug delivers durable remissions or merely delays progression. Moreover, pancreatic cancer’s notorious heterogeneity and rapid evolution may lead to acquired resistance mechanisms that could limit elraglusib’s durability, especially if used as a monotherapy or in non-optimized combinations. The reliance on GSK-3 beta inhibition also carries potential safety concerns, as this pathway is involved in metabolic regulation, neuronal function, and tissue homeostasis; although no major safety signals were reported in the released data, chronic inhibition could pose risks in longer treatment regimens or broader patient populations, particularly if combined with other myelosuppressive or hepatotoxic agents.
The company’s pipeline remains heavily concentrated on a single asset, elraglusib, with no other clinical-stage programs disclosed in the provided information, creating significant binary risk for investors. Success is contingent almost entirely on the outcome of future Phase 3 trials in pancreatic cancer, and any delay, negative readout, or safety issue could severely impair valuation with limited diversification to fall back on. Additionally, while the lead investigator speculated about broader applications across tumor types, no data from other cancer indications were presented in the news, meaning such expansion remains purely hypothetical at this stage and would require entirely new clinical programs, further diluting timelines and resources. The oncology landscape is also intensely competitive, with numerous companies developing GSK-3 inhibitors, KRAS-targeted therapies (particularly relevant in pancreatic cancer where KRAS G12C and other mutations are prevalent), TGF-β modulators, and neoantigen vaccines—any of which could surpass elraglusib in efficacy or safety profile. Furthermore, the lack of a recent earnings call means there is no direct insight into management’s cash runway, burn rate, or funding plans; if the company is undercapitalized, it may need to dilute shareholders through additional financing to reach key milestones, potentially at unfavorable terms. Given that pancreatic cancer trials often require lengthy follow-up to assess overall survival—a primary endpoint in the mid-stage study—any extension in trial duration due to slower-than-expected event rates could increase costs and delay readouts, exacerbating financial strain. Without clear visibility into partnership interest, licensing discussions, or non-dilutive funding sources, the path to commercialization appears uncertain and fraught with execution risk.

Despite the promising survival signals in the mid-stage pancreatic cancer trial, Actuate Therapeutics faces substantial hurdles in translating early-phase efficacy into a commercially viable product, particularly given the high failure rate of oncology drugs in Phase 3 development. The trial, while showing a doubling of one-year survival, was still intermediate in size (233 patients) and not designed to support regulatory approval; thus, any positive outcome would require replication in a larger, pivotal trial that could take years to complete and enroll, especially in a competitive landscape where multiple companies are pursuing novel pancreatic cancer therapies. The fact that only 13% of patients were alive at two years in the drug group—while dramatically better than zero in the control arm—still underscores the modest absolute benefit in long-term survival, raising questions about whether the drug delivers durable remissions or merely delays progression. Moreover, pancreatic cancer’s notorious heterogeneity and rapid evolution may lead to acquired resistance mechanisms that could limit elraglusib’s durability, especially if used as a monotherapy or in non-optimized combinations. The reliance on GSK-3 beta inhibition also carries potential safety concerns, as this pathway is involved in metabolic regulation, neuronal function, and tissue homeostasis; although no major safety signals were reported in the released data, chronic inhibition could pose risks in longer treatment regimens or broader patient populations, particularly if combined with other myelosuppressive or hepatotoxic agents.
The company’s pipeline remains heavily concentrated on a single asset, elraglusib, with no other clinical-stage programs disclosed in the provided information, creating significant binary risk for investors. Success is contingent almost entirely on the outcome of future Phase 3 trials in pancreatic cancer, and any delay, negative readout, or safety issue could severely impair valuation with limited diversification to fall back on. Additionally, while the lead investigator speculated about broader applications across tumor types, no data from other cancer indications were presented in the news, meaning such expansion remains purely hypothetical at this stage and would require entirely new clinical programs, further diluting timelines and resources. The oncology landscape is also intensely competitive, with numerous companies developing GSK-3 inhibitors, KRAS-targeted therapies (particularly relevant in pancreatic cancer where KRAS G12C and other mutations are prevalent), TGF-β modulators, and neoantigen vaccines—any of which could surpass elraglusib in efficacy or safety profile. Furthermore, the lack of a recent earnings call means there is no direct insight into management’s cash runway, burn rate, or funding plans; if the company is undercapitalized, it may need to dilute shareholders through additional financing to reach key milestones, potentially at unfavorable terms. Given that pancreatic cancer trials often require lengthy follow-up to assess overall survival—a primary endpoint in the mid-stage study—any extension in trial duration due to slower-than-expected event rates could increase costs and delay readouts, exacerbating financial strain. Without clear visibility into partnership interest, licensing discussions, or non-dilutive funding sources, the path to commercialization appears uncertain and fraught with execution risk.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	663.08 Bn	31.49	6.77	60.73 Bn
2	ABBV	AbbVie Inc.	primary	453.04 Bn	71.80	7.04	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	370.87 Bn	117.16	5.57	53.91 Bn
4	NVS	Novartis Ag	primary	305.29 Bn	10.77	4.44	9.59 Bn
5	PFE	Pfizer Inc	primary	162.10 Bn	37.11	2.54	63.19 Bn
6	SNY	Sanofi	primary	53.95 Bn	11.58	1.01	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	45.00 Bn	-25.05	-	-
8	INCY	Incyte Corp	primary	25.47 Bn	15.75	4.38	0.04 Bn

Actuate Therapeutics ACTU

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password